Pharmaceutical companies Mylan NV, Pfizer, and other pharmaceutical companies lost their bid to end antitrust litigation brought by nearly every state attorney general over an alleged industrywide scheme to inflate the cost of generic dermatology products, reported Bloomberg.
Featured News
California Pushing Back Against Federal Preemption of Its Privacy Laws
May 7, 2026 by
CPI
Rave Sues Apple in Antitrust Case Over App Store Removal
May 7, 2026 by
CPI
Trivago Files Antitrust Case Against Google in Germany Over Search Practices
May 7, 2026 by
CPI
A New Idea Is Gaining Ground: Tax AI Computing Power to Offset Job Losses
May 7, 2026 by
CPI
Morocco Competition Authority Opens Antitrust Probe Into Luxury Beauty Market
May 7, 2026 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Unilateral Effects
Apr 28, 2026 by
CPI
A Net Present Value Approach to Merger Analysis
Apr 28, 2026 by
Joseph J Simons & Malcolm Coate
Generative AI and Competitive Disruption: Increasingly Relevant for Merger Analysis?
Apr 28, 2026 by
Andrea Coscelli, Emily Chissell, Nitika Bagaria & Tega Akati-Udi
Non-Price Unilateral Effects In Media Mergers
Apr 28, 2026 by
Lapo Filistrucchi & Teresa Oriani
Ecosystem Mergers and Unilateral Effects? A Framework for Assessing the Ecosystem Theory of Harm
Apr 28, 2026 by
Ethel Fonseca, George Tucker & Helder Vasconcelos